Trials / Conditions / Bronchial Neoplasms

Bronchial Neoplasms

20 registered clinical trials studyying Bronchial Neoplasms — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study NCT06494241	AstraZeneca	—
Active Not Recruiting	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC NCT06376084	AstraZeneca	—
Recruiting	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-S NCT06177925	Nanfang Hospital, Southern Medical University	Phase 2
Terminated	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873	Blueprint Medicines Corporation	Phase 1
Terminated	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408	Blueprint Medicines Corporation	Phase 1
Terminated	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780	Blueprint Medicines Corporation	Phase 1
Terminated	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315	Hoffmann-La Roche	Phase 2
Completed	Cryotechnique as a Diagnostic and Therapeutic Tool of Endobronchial Tumors NCT06531265	Sohag University	N/A
Terminated	Evaluation of a New Open Source Virtual Bronchoscope Navigation System NCT03745859	Norwegian University of Science and Technology	—
Completed	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations NCT03516214	University of Cologne	Phase 1
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Completed	Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452	Syndax Pharmaceuticals	Phase 1
Completed	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778	Syndax Pharmaceuticals	Phase 1
Unknown	Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients NCT02804100	Wenzhou Medical University	—
Completed	Navigated EBUS and Functional Imaging in Lung Cancer NCT02745002	St. Olavs Hospital	N/A
Completed	Icotinib for Completed Resected IB NSCLC With EGFR Mutation NCT02264210	Sun Yat-sen University	Phase 2
Terminated	ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT NCT02050724	Cantonal Hospital of St. Gallen	Phase 2
Unknown	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial NCT03402048	University of Turin, Italy	Phase 3
Completed	Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS NCT02493023	St. Olavs Hospital	N/A
Completed	Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CR NCT01261585	Centre Henri Becquerel	—